<DOC>
	<DOCNO>NCT01243788</DOCNO>
	<brief_summary>To determine efficacy safety Salmeterol/Fluticasone Propionate 50/500ug BID v Ipratropium/Albuterol 36/206ug QID Chinese patient moderate-to-severe Chronic Obstructive Pulmonary Disease ( COPD ) .</brief_summary>
	<brief_title>The Efficacy Safety Salmeterol/Fluticasone Propionate v Atropium/Albuterol Patients COPD</brief_title>
	<detailed_description>- This 12-week , multicentre , randomize , open-label , active-controlled , paralleled-group study . - Chinese patient age ≥40 year moderate-to-severe COPD eligible study . 1 . If satisfying entry criterion , patient enter 8 14 day run-in period , replace previous bronchodilator inhale nebulized Salbutamol . 2 . Patients record daily severity rating daytime symptom shortness breath , tiredness , activity limitation , frustration symptom , night-time sleep symptom daily card . 3 . Each symptom rat use 0-100 visual analog scal ( VAS ) . For overall assessment daytime symptom , combine symptom score obtain add VAS score shortness breath , tiredness , activity limitation , frustration symptom . 4 . Patients require symptomatic demonstrate combined daytime symptom score 120 least 4 7 day prior randomization . 1 . Eligible patient randomize ( 1:1 ) follow 2 treatment 12 week . 1 . Inhaled Salmeterol/Fluticasone propionate 50/500ug twice daily inhale IB/ALB 36/206ug QID . 2 . Salbutamol provide relief symptom `` require '' basis whole 12 week . 2 . A Follow-up visit conduct 2 week completion treatment/early withdrawal assess adverse effect discontinue study treatment .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Chinese male female outpatient age 40 79 year , inclusive Patients establish diagnosis COPD , define GOLD guideline postbronchodilation FEV1/FVC ratio &lt; 70 % , AND Postbronchodilation FEV1 % predict ranged ≥25 ≤70 . A cigarette smoke history 10 packyears Use oral theophylline , inhaled medication LABA , LAMA , ICS for≥30 day ( e.g . SABA , SAMA ) Patients able use Accuhaler device relief medication Patients willing give inform consent participate study comply study protocol Eligible female childbearing potentia Patients concurrent respiratory disorder ( e.g . asthma ) COPD Patients requirement regular long term oxygen therapy ( &gt; 12h/d ) Patients use inhaled oral steroid within 30 day screen Patients respiratory tract infection require antibiotic within 14 day screen Patients moderatetosevere COPD exacerbation within 30 day screen Patients significant medical condition disease would place patient risk interfere study evaluation . Patients used inhibitory agent ( e.g . b blocker ) within 14 day screen Female patient pregnant may pregnant study duration</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>COPD</keyword>
	<keyword>Seretide</keyword>
	<keyword>Combivent</keyword>
	<keyword>effect safety</keyword>
	<keyword>Twelve week</keyword>
</DOC>